Ping Li1
Xiaoying Zhang2Shu Chen1Po-lin Hsu2Tingting Wu2Shirui Qian1Wei Su1
Guohua Wang1
Nianguo Dong1*- 1Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
- 2magAssist, Inc., Suzhou, Jiangsu, China
Introduction: Mechanical circulatory support (MCS) can help to maintain hemodynamic stability, improve cardiac function, reduce cardiac load, and is an important method for the treatment of advanced heart failure. However, traditional MCS systems [IABP, Impella, TandemHerat, veno-arterial extracorporeal membrane oxygenation (VA-ECMO)] are associated with limitations including trauma, a high rate of complications (hemolysis, bleeding) and require complex care from nurses.
Case summary: We report a case of left heart failure resulting from dilated cardiomyopathy in a 24 years-old man. A catheter was placed through the right jugular vein and a drainage tube was positioned under ultrasound guidance through the superior vena cava, right atrium, atrial septum, to the left atrium, and returned to the axillary artery using an extracorporeal magnetic levitation ventricular assist device (VAD). The patient was successfully supported for 10 days and bridged to heart transplant.
Discussion: To the best of our knowledge, this is the first report of the use of an extracorporeal magnetic levitation VAD for MCS via a percutaneous approach. Our findings support the wider use of this strategy for patients awaiting myocardial recovery or who require heart bridging or transplantation.
Introduction
In China, common treatments for temporary mechanical circulatory support (MCS) in patients with cardiogenic shock (CS) include intra-aortic balloon pump (IABP) and veno-arterial extracorporeal membrane oxygenation (VA-ECMO). Although the IABP is simple to operate, the results of the SHOCK-II clinical trial showed that IABP had no clear effect on improving survival in patients with CS (1); Similarly, although VA-ECMO increases systemic flow and pressure and reduces venous congestion in pulmonary circulation without unloading the left side of the heart (2), it can lead to major complications including pump thrombosis, bleeding, ischemic limbs, and harlequin syndrome (3). Therefore, more options for MCS and more suitable implantation strategies are needed to improve prognosis in patients with CS.
The extracorporeal magnetic levitation ventricular assist device (VAD) uses a magnetic levitation rotor that can rotate without friction or wear, with less blood stagnation, turbulence or hemolysis, compared with ECMO and almost no mechanical failure (4). In our previous report, we treated a patient who developed CS following coronary artery bypass surgery for 9 days until discharge using magnetic levitation extra-VAD (5). However, this device needs to be inserted by median sternotomy, which is highly invasive and inconvenient for patients. We modified our approach and performed percutaneous left VAD placement through the right internal jugular vein, with cannulation of the axillary artery for 10 days to successfully bridge the patient to heart transplantation. This method was well-tolerated and associated with less trauma and simplified operation compared with CentriMag, which maximizes patient benefits.
Case report
A 24 years-old man (height: 185 cm; weight: 78 kg) with a history of dilated cardiomyopathy, pulmonary hypertension, severe mitral insufficiency, and moderate tricuspid insufficiency was admitted with a New York Heart Association (NYHA) cardiac function rating of IV and a left ventricular ejection fraction of 20%. He received extensive medical treatment to increase myocardial contractility, reduce pulmonary hypertension and control heart rate. Unfortunately, the patient developed persistent systemic hypoperfusion with CS. He was given temporary left ventricular assist using a magnetic levitation extra-VAD device. Before implantation, ultrasound examination showed left ventricular dilatation (left ventricular end-diastolic diameter 9.5 cm), systolic dysfunction [left ventricular ejection fraction 13%; arterial blood pressure 80/60 mmHg; N-terminal pro-B-type natriuretic peptide (NT-proBNP) 2,910 pg/ml], and pulmonary artery systolic blood pressure of 57 mmHg.
To circumvent the difficulties of atrial septal puncture through the jugular vein, puncture through the femoral vein was performed. A guide wire was inserted through the right femoral vein puncture to achieve right heart catheterization under the guidance of ultrasound and digital subtraction angiography (DSA) (Figure 1A, and a snare was placed in the right atrium along the femoral vein guide wire (Figure 1B). The catheter was delivered through the right jugular vein, captured by a snare, and placed into the left atrium along the femoral vein guide wire (Figure 1C). A drainage tube was placed using the guide wire approach to establish a drainage path through the jugular vein, superior vena cava, right atrium, and atrial septum to the left atrium (Figure 1D). Finally, the axillary artery was exposed and blocked under the right clavicle, an 8 mm artificial blood vessel was anastomosed end-to-side, and the outflow tube was inserted to establish left atrium-extra-VAD-axillary artery circulation assistance. The pump flow was set at approximately 3 L/min and the speed was 2,500 rpm.
Figure 1. Percutaneous intubation procedure. (A) Atrial septal puncture. (B) Insertion of the snare. (C) Jugular guide wire creates a passage in the left atrium. (D) Drainage tube placement.
Hemodynamic and hematological parameters were monitored throughout extra-VAD implantation, and indicated good recovery. No hemolysis-related complications occurred (Figure 2A), and liver and kidney function were unaffected (Table 1). Heparin was used for anticoagulation therapy to maintain the target activated coagulation time (ACT) between 180 and 220 s and maintain the target activated partial thromboplastin time (APTT) between 40 and 55 s (Figure 2B). High-sensitivity troponin I reached 2,985.1 ng/L postoperatively and rapidly decreased to 647.7 ng/L on the second postoperative day. Similarly, lactic acid levels decreased to 0.6 mmol/L the day after surgery and remained between 0.4 and 1.0 mmol/L thereafter. These results indicated a rapid improvement in cardiac function. The extra-VAD device was removed 10 days later, and ultrasound results showed a left ventricular end-diastolic diameter of 7.6 cm. The patient subsequently underwent a successful heart transplant.
Figure 2. Lab rest results during extra- ventricular assist device (VAD) support. (A) Blood compatibility. PLT, platelet; RBC, red blood cell; WBC, white blood cell. (B) Anticoagulation management. ACT, active clotting time (s); APTT, activated partial thromboplastin time (s); D-Dimer (mg/L).
Table 1. Lab rest results during extra- ventricular assist device (VAD) support.
Discussion
Cardiogenic shock is a recognized cause of death in patients with heart failure due to low cardiac output resulting in severe hypoperfusion of vital organs, with a short-term mortality rate of more than 50% (6). MCS can quickly stabilize hemodynamic parameters, ensure effective perfusion of organs, and improve cardiac function. In recent years, clinicians have increasingly used short-term MCS to improve adverse outcomes in patients with CS (7).
Traditional short-term MCS units such as Impella, TandemHerat, and VA-ECMO use mechanical bearing axial flow pumps. In contrast, the magnetic levitation centrifugal pump increases blood compatibility and reduces the incidence of pump thrombosis, hemolysis, and gastrointestinal bleeding, thereby minimizing blood loss, the need for blood transfusion, and postoperative inflammation (8, 9). In addition, reduced thrombosis minimizes the amount of anticoagulation required to prevent thrombosis; therefore, postoperative anticoagulation management is simpler compared with VA-ECMO.
In addition, only CentriMag can offer full circulatory support; the rest of the device such as Impella CP with up to 4.3 L/min, Impella 5.5 with 5.5 L/min (Axial pump may overestimate the flow rate due to the number are not directly reading from ultrasonic flow sensor) and TandemHeart with 4 L/min can only provide partial support. In life threatening end stage heart failure patient, the support average flow range is from approximately 3.5–6.0 L/min (10). In these cases, impella or TandemHeart may not provide sufficient flow for the patients. Therefore, ECMO and Impella (ECPELLA) are combined to treat cardiogenic shock (11). However, combining two different mechanical circulatory support systems will potentially increase complications.
No bleeding or thrombotic complications and no hemolysis were observed during the entire course of circulatory support, which is consistent with our previous report (5). While our method of extra-VAD is designed for short-term use (≤30 days), we have found it to be well-tolerated over longer periods of time.
In addition, we modified the conventional method of median sternotomy and re-cannulation to a percutaneous approach. To our knowledge, this is the first time this surgical method has been reported in the literature and suggests that minimally invasive, short-term and mid-term external magnetic levitation artificial heart implantation should be considered for widespread use.
Percutaneous left VAD reduces left ventricular volume, wall stress, and myocardial oxygen consumption whilst increasing cardiac output and coronary perfusion to minimize myocardial ischemia and hemodynamic failure in high-risk patients with heart failure. This minimally invasive method greatly reduces patient trauma and avoids the risks associated with complicated thoracotomy (12).
Additionally, the percutaneous approach reduces blood loss and potential coagulation disorders, which simplifies postoperative care (13). With transjugular intubation, patients may walk early after surgery, which can accelerate postoperative activity and rehabilitation and reduce the occurrence of postoperative bed rest complications such as deep vein thrombosis and pulmonary infection (14). In addition to clinical benefits, this minimally invasive approach can significantly shorten the length of hospital stay, restore cardiac function more rapidly and greatly reduce medical costs compared with established approaches (15).
In conclusion, we propose a novel, minimally invasive and easy-to-care mode of extracorporeal ventricular assistance using an extracorporeal magnetic levitation VAD via jugular vein intubation. This model avoids unnecessary surgeries and is associated with fewer complications than existing methodologies. Further clinical data are necessary to evaluate the advantages of this model over traditional MCS strategies.
Data availability statement
The original contributions presented in this study are included in this article/supplementary material, further inquiries can be directed to the corresponding author.
Ethics statement
The studies involving human participants were reviewed and approved by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. The patients/participants provided their written informed consent to participate in this study.
Author contributions
PL: data curation, formal analysis, methodology, software, validation, visualization, and writing—original draft. XZ: methodology, investigation, validation, software, and formal analysis. SC and P-LH: methodology, validation, and writing—review and editing. TW and SQ: writing—review and editing. WS and GW: resources and supervision. ND: conceptualization, review and editing, supervision, and funding acquisition. All authors reviewed the manuscript and approved the submitted version.
Funding
This work was supported by the National Natural Science Foundation of China (81930052).
Acknowledgments
The authors acknowledge all who made contributions for the case diagnosis, therapy, and decision-making process.
Conflict of interest
XZ, P-LH, and TW were employed by magAssist, Inc.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Abbreviations
MCS, mechanical circulatory support; VA-ECMO, veno-arterial extracorporeal membrane oxygenation; VAD, ventricular assist device; IABP, intra-aortic balloon pump; CS, cardiogenic shock.
References
1. Thiele H, Schuler G, Neumann F, Hausleiter J, Olbrich H, Schwarz B, et al. Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: design and rationale of the intraaortic balloon pump in cardiogenic shock II (IABP-SHOCK II) trial. Am Heart J. (2015) 169:E3–4. doi: 10.1016/j.ahj.2014.11.001
2. Mohite P, Sabashnikov A, Koch A, Binu R, Padukone A, Kaul S, et al. Comparison of temporary ventricular assist devices and extracorporeal life support in post-cardiotomy cardiogenic shock. Interact Cardiovasc Thorac Surg. (2018) 27:863–9.
3. Telukuntla K, Estep J. Acute mechanical circulatory support for cardiogenic shock. Methodist Debakey Cardiovasc J. (2020) 16:27–35. doi: 10.14797/mdcj-16-1-27
4. Takayama H, Soni L, Kalesan B, Truby L, Ota T, Cedola S, et al. Bridge-to-decision therapy with a continuous-flow external ventricular assist device in refractory cardiogenic shock of various causes. Circ Heart Fail. (2014) 7:799–806. doi: 10.1161/CIRCHEARTFAILURE.113.000271
5. Li P, Wu L, Dong N. First experience of magnetically levitated extracorporeal left ventricular assist device for cardiogenic shock in China. Esc Heart Fail. (2022) 9:1471–3.
6. Jentzer J, van Diepen S, Barsness G, Henry T, Menon V, Rihal C, et al. Cardiogenic shock classification to predict mortality in the cardiac intensive care unit. J Am Coll Cardiol. (2019) 74:2117–28. doi: 10.1016/j.jacc.2019.07.077
7. Balthazar T, Vandenbriele C, Verbrugge F, Den Uil C, Engstroem A, Janssens S, et al. Managing patients with short-term mechanical circulatory support JACC review topic of the week. J Am Coll Cardiol. (2021) 77:1243–56. doi: 10.1016/j.jacc.2020.12.054
8. Mehra M, Goldstein D, Uriel N, Cleveland J, Yuzefpolskaya M, Salerno C, et al. Two-year outcomes with a magnetically levitated cardiac pump in heart failure. N Engl J Med. (2018) 378:1386–95. doi: 10.1056/NEJMoa1800866
9. Mohite P, Zych B, Popov A, Sabashnikov A, Saez D, Patil N, et al. CentriMag (R) short-term ventricular assist as a bridge to solution in patients with advanced heart failure: use beyond 30 days. Eur J Cardiothorac Surg. (2013) 44:E310–5. doi: 10.1093/ejcts/ezt415
10. John R, Long J, Massey H, Griffith B, Sun B, Tector A, et al. Outcomes of a multicenter trial of the levitronix CentriMag ventricular assist system for short-term circulatory support. J Thorac Cardiovasc Surg. (2011) 141:932–9. doi: 10.1016/j.jtcvs.2010.03.046
11. Nakamura M, Imamura T. Practical management of ECPELLA. Int Heart J. (2020) 61:1094–6. doi: 10.1536/ihj.20-172
12. Saeed D, Maxhera B, Kamiya H, Lichtenberg A, Albert A. Alternative right ventricular assist device implantation technique for patients with perioperative right ventricular failure. J Thorac Cardiovasc Surg. (2015) 149:927–32. doi: 10.1016/j.jtcvs.2014.10.104
13. Vieira J, Ventura H, Mehra M. Mechanical circulatory support devices in advanced heart failure: 2020 and beyond. Prog Cardiovasc Dis. (2020) 63:630–9. doi: 10.1016/j.pcad.2020.09.003
14. Sweity E, Alkaissi A, Othman W, Salahat A. Preoperative incentive spirometry for preventing postoperative pulmonary complications in patients undergoing coronary artery bypass graft surgery: a prospective, randomized controlled trial. J Cardiothorac Surg. (2021) 16:241. doi: 10.1186/s13019-021-01628-2
Keywords: extracorporeal ventricular assist device, maglev, percutaneous mechanical circulatory support, minimally invasive, heart failure
Citation: Li P, Zhang X, Chen S, Hsu P-l, Wu T, Qian S, Su W, Wang G and Dong N (2023) Case report: Successful percutaneous extracorporeal magnetic levitation ventricular assist device support in a patient with left heart failure due to dilated cardiomyopathy. Front. Cardiovasc. Med. 10:1093794. doi: 10.3389/fcvm.2023.1093794
Received: 09 November 2022; Accepted: 02 January 2023;
Published: 19 January 2023.
Edited by:
Matteo Cameli, University of Siena, ItalyReviewed by:
Teruhiko Imamura, University of Toyama, JapanMichael Dandel, German Center for Cardiovascular Research (DZHK), Germany
Copyright © 2023 Li, Zhang, Chen, Hsu, Wu, Qian, Su, Wang and Dong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Nianguo Dong, 
ZG9uZ25pYW5ndW9AaG90bWFpbC5jb20=